Evidence map›Paper›PMID 35034327›Full record

ArticleInfection2022

Therapeutic efficacy of chloroquine for uncomplicated Plasmodium vivax malaria in southeastern and western border areas of Myanmar.

Myat Thu Soe, Pyae Linn Aung, Myat Htut Nyunt, Myint Myint Sein, Cho Cho, Zhaoqing Yang, Lynette Menezes, Daniel M Parker, Myat Phone Kyaw, Liwang Cui

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Myat Thu Soe *Myanmar Health Network Organization, Yangon, Myanmar.
Pyae Linn Aung *Myanmar Health Network Organization, Yangon, Myanmar.
Myat Htut NyuntDepartment of Medical Research, Ministry of Health and Sports, Yangon, Myanmar.
Myint Myint SeinDepartment of Microbiology, University of Medicine, Magway, Myanmar.
Cho ChoMyanmar Health Network Organization, Yangon, Myanmar.
Zhaoqing YangDepartment of Pathogen Biology and Immunology, Kunming Medical University, Kunming, 650500, Yunnan, People's Republic of China.
Lynette MenezesDivision of Infectious Diseases and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA.
Daniel M ParkerDepartment of Population Health and Disease Prevention, Department of Epidemiology, University of California, Irvine, USA.
Myat Phone KyawMyanmar Health Network Organization, Yangon, Myanmar. kyaw606@gmail.com.
Liwang CuiDivision of Infectious Diseases and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA. liwangcui@usf.edu.ORCID http://orcid.org/0000-0002-8338-1974
Myanmar Oxford Clinical Research Unit · MMUniversity of South Florida · USKunming Medical University · CNMinistry of Health and Sports · MMUniversity of California, Irvine · USUniversity of Medicine Magway · MM

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
NIAID NIH HHS U19 AI089672the national institutes of health U19AI089672
6 · The paper itself

Abstract

backgroundIn the Greater Mekong Subregion of Southeast Asia, Plasmodium vivax malaria is endemic and causes significant morbidity. In this study, the efficacy of chloroquine for treating uncomplicated P. vivax malaria at the eastern and western borders of Myanmar was investigated.

methodsA total of 197 participants with microscopically confirmed P. vivax infection were enrolled from three townships of the southeastern (Thanbyuzayat and Kawthoung) and western (Kyauktaw) borders of Myanmar. Patients were treated with chloroquine according to the national malaria treatment guidelines and followed for 28 days.

resultsAmong the 197 enrollments, 172 completed the 28-day follow-up. Twelve recurrent P. vivax infections, all occurring in the third and fourth week, were detected, resulting in an overall cumulative rate of recurrence of 4.7% [95% confidence interval (CI) 1.5-7.8]. The incidence rate of recurrence varied among the three sites. In Thanbyuzayat township, no patients had recurrent parasitemia between days 7 and 28. In contrast, Kyauktaw township had a day 28 cumulative incidence rate of recurrence of 7.2% (95% CI 0.6-13.9%) compared to 6.9% (95% CI 0.6-13.2) in Kawthoung township.

conclusionWhile this study confirmed the relatively high clinical efficacy of chloroquine for treating P. vivax in Myanmar with modest rates of recurrent infections within 28 days of the treatment, it also revealed considerable geographical heterogeneity of chloroquine efficacy, which warrants continuous surveillance efforts.

Indexed as

AntimalarialsMalaria, VivaxChloroquineHumansMyanmarPlasmodium vivaxAntimalarialsChloroquineChloroquineClinical efficacyMyanmarPlasmodium vivaxRecurrent parasitemia

Identifiers

PMID35034327
PMCPMC9383049
OpenAlexW4205736385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.